Phase II Study of Bortezomib (PS-341) for Patients With Advanced Bronchiolo-Alveolar Carcinoma (BAC) or Adenocarcinoma With BAC Features
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2016
At a glance
- Drugs Bortezomib (Primary)
- Indications Bronchiolo-alveolar adenocarcinoma; Lung cancer
- Focus Biomarker; Therapeutic Use
- 20 Nov 2012 Status changed from completed to recruiting as reported by ClinicalTrials.gov.
- 14 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Oct 2010 Planned end date changed from 1 Dec 2008 to 1 Dec 2010 as reported by ClinicalTrials.gov.